Dan V Iosifescu, MD
- ADJUNCT ASSOCIATE PROFESSOR | Psychiatry
Dr. Dan Iosifescu is the Director of the Adult Psychopharmacology in the Mount Sinai Behavioral Health System and Associate Professor of Psychiatry and Neuroscience at the Icahn School of Medicine at Mount Sinai. Dr. Iosifescu’s research is focused on biological markers of treatment outcome in mood disorders, using neuroimaging (MRI, MRS) and neurophysiology (quantitative EEG) techniques to investigate structural, biochemical, and functional brain abnormalities in mood disorders and their impact on clinical treatment. Dr. Iosifescu is also interested in the evaluation and treatment of cognitive deficits in mood and anxiety disorders.
After receiving his M.D. from the Institute of Medicine and Pharmacy in Bucharest, Romania, Dr. Iosifescu completed his internship and psychiatry residency at Massachusetts General Hospital and McLean Hospital, serving as chiefresident in consultation-liaison psychiatry. His research training included a neuroimaging fellowship in the Neuroscience Laboratory at Harvard Medical School, a psychopharmacology fellowship in the MGH Mood and Anxiety Disorders Institute, and a fellowship in the Clinical Investigator Training Program at Harvard and MIT. In parallel Dr. Iosifescu received a Master of Medical Science degree from Harvard University. Before 2010 he was Associate Professor of Psychiatry at Harvard Medical School and Director of Translational Neuroscience in the Depression Clinical and Research Program and Site Director of the Bipolar Trials Network, both at Massachusetts General Hospital. Between 2010 and 2015 he was the Director of the Mood and Anxiety Disorders Program at Mount Sinai.
Dr. Iosifescu has authored more than 100 papers in peer-reviewed medical journals, nine book chapters and more than 100 abstracts. He received a series of prestigious prizes: the NARSAD Young Investigator Award (which he received twice), the Kaplen Award and the Livingston Award from Harvard Medical School, the APA Young Investigator Award, the NCDEU New Investigator Award, and a National Institute for Mental Health K23 Career Development Award. Dr. Iosifescu was also designated among the “Best Doctors in America” in all editions of “Best Doctors” since 2005 and among the “Top Doctors” by Castle Connolly since 2015.
In the News Dr. Iosifescu discusses depression and bipolar disorder in The Daily News feature The Daily Check Up.
Financial & Billing Information
Please direct any detailed billing or financial inquires to the Mount Sinai Psychiatry billing customer service number at 212-659-8752.
- Bipolar Disorder
Master of Medical Science, Harvard Medical School
- Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression
This study is looking at the efficacy, durability, safety, and tolerability of multiple single doses of Ketamine vs. active placebo for treating patients with treatment resistant depression who are taking an antidepressant that is not working for them. Ketamine is a Food and D...
- A Phase 3 Multicenter Study of the Long-term Safety and Tolerability of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults who Have an Inadequate Response to Antidepressant Therapy (the FORWARD-2 Study)
The purpose of this Phase 3 trial is to assess the long-term safety and tolerability of ALKS 5461 for use as a potential adjunct treatment for major depressive disorder (MDD) in adults who have not responded adequately to traditional antidepressant therapy. ALKS 5461 is a fixe...
- The Efficacy and Safety of Galantamine for Dysfunction in Bipolar Disorder
This research study is evaluating a medication that helps with memory in patients with bipolar disorder. This research study examines the effectiveness of galantamine compared to placebo (contains no active medication) in the treatment of bipolar patients who complain of every...
- Evaluation of NK1 Antagonist in Post-Traumatic Stress
The purpose of this study is to test the safety and effectiveness of an experimental drug for PTSD, GSK561679, compared to a placebo, which is a pill with no active substance. Patients may qualify for participation in this study if they have a diagnosis of PTSD, and have curre...
- A Prospective, Double Blind, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the H1-Coil deep Transcranial Magnetic Stimulation (TMS) in conjunction with mood stabilizers in Subjects with Bipolar Depression
The purpose of the study is to evaluate the efficacy and safety of H1-Coil deep brain rTMS (dTMS) in subjects with bipolar depression, taking mood stabilizers and previously unsuccessfully treated with antidepressant medications. dTMS is a experimental device and is not approv...
- Double-Blind, Proof-of-Concept (POC) Trial of Low Field Magnetic Stimulation (LFMS) Augmentation of Antidepressant Therapy in Treatment-Resistant Depression (TRD)
The purpose of this study is to look at the efficacy and safety of Low Field Magnetic Stimulation (LFMS) as a rapid antidepressant treatment for patients with hard to treat depression who are currently on an antidepressant medication that is working for them. In past tri...
- Specificity and Validity of Oxidative Stress Model of Chronic Fatigue Syndrome
The purpose of this study is to explore the different in brain function between those subjects with Chronic Fatigue Syndrome and those with major depressive disorder (MDD). This study involves one screening visit at Mount Sinai and one MRI scan conducted at Cornell Medical Cen...
- Dopamine and Motivation in Depression
This study seeks to investigate low reward motivation in patients with major depressive disorder (MDD) by focusing specifically on levels of dopamine in the brain. We are looking for depressed participants who have not used antidepressant medications in the past. Patients will...